Latest news with #EquityInsiderNews
Cision Canada
11-07-2025
- Business
- Cision Canada
Quantum Era Risks Put Future-Proof Cybersecurity on Every Investor's Radar
Issued on behalf of Scope Technologies Corp. VANCOUVER, BC, July 11, 2025 /CNW/ -- Equity Insider News Commentary – Computing power is accelerating faster than it ever has since the computer was invented. However, with that, so too has the risk potential towards our digital data. According to the 2025 Data Threat Report, 74% of the companies surveyed in Germany view rapid AI advances as the top security risk associated with GenAI. In the UK, the new 10-year economic plan is set to be shaped by AI, cybersecurity, and quantum computing. In Singapore, ST Engineering recently held its largest Cybersecurity Summit to date, with over 1,000 leaders from government, industry and academia, with aims to address growing cyber threats coming from quantum and AI. Clearly the issue of increased threats to cybersecurity coming from AI and quantum computing is a global issue, and advancing the potential counter protection to this are several future-proof advocates with developments coming from Scope Technologies Corp. (CSE: SCPE) (OTCQB: SCPCF), Allot Ltd. (NASDAQ: ALLT), Advanced Micro Devices, Inc. (NASDAQ: AMD), Datadog, Inc. (NASDAQ: DDOG), and STMicroelectronics N.V. (NYSE: STM). Grand View Research predicts sales of post-quantum cryptography will rise 37.6% per year through 2030. Research and Markets is even more upbeat, calling for 41.47% annual growth and a market worth about US$17.7 billion by the end of the decade. That surge is already opening fresh entry points for retail investors looking to get in early. Scope Technologies Corp. (CSE: SCPE) (OTCQB: SCPCF) is a quantum-focused cybersecurity company best known for Quantum Security Entropy (QSE), its cloud platform that locks files and messages inside quantum-resilient encryption and a zero-trust framework. QSE uses randomness drawn from quantum processes to stop both today's hackers and tomorrow's "harvest now, decrypt later" attacks. Earlier this week, Scope strengthened its team for the second time in a month, tapping Microsoft and Electronic Arts alumnus Andrew Knight to serve as Vice-President of Product—a hire that caps six weeks of rapid leadership change and signals fresh momentum for the company's quantum-ready security platform. Knight's task is clear: accelerate the road map for Quantum Security Entropy (QSE), the cloud platform that stores files and messages inside quantum-resilient encryption. QSE pairs zero-trust architecture with true entropy—randomness drawn from quantum processes—to stop both today's hackers and tomorrow's "harvest now, decrypt later" attacks. "I'm incredibly excited to join Scope Technologies at such a transformative time," said Knight. "The rise of quantum threats demands proactive solutions, and QSE is uniquely positioned to deliver. I look forward to helping shape its next evolution—bringing together my experience in scalable production pipelines, external ecosystems, and secure product innovation." Knight brings almost twenty years of experience guiding cross-functional game and cloud projects, most recently at Microsoft's Coalition Studios. At Scope he will channel that know-how into speeding up the road map for QSE, the firm's quantum-resilient encryption platform. His brief covers everything from new feature design to partner integrations, giving QSE a product chief who speaks the language of both engineers and enterprise buyers. His arrival follows the June promotion of long-time product lead Ted Carefoot to Chief Executive Officer, a move that shifted the company's focus from R & D to go-to-market execution. Carefoot's background in governance, risk, and compliance shaped QSE's zero-trust architecture and HIPAA-aligned security posture, and industry watchers expect that focus on regulation to continue under his watch. Together, the newly-appointed duo brings decades of game-scale infrastructure, compliance, and enterprise sales experience to a platform already benchmarked at millions of encrypted messages per second. "As Scope Technologies scales its business, having the right leadership at the intersection of technology, operations, and strategic partnerships is key," said Carefoot. "Andrew brings a rare combination of deep technical execution and commercial strategy honed across several sectors such as digital interactive media. Procurement, and partner relationships. His leadership will be central as we evolve QSE's architecture and expand its adoption across enterprise security environments." At the upcoming DEF CON 33 conference in Las Vegas in August, Scope Technologies will step onto the main stage at Quantum Village to outline how quantum algorithms could power a new wave of malware that cracks passwords, hijacks live sessions, and breaks crypto-wallet keys in real time. The talk, led by Carefoot and titled "Quantum Malware: The Emerging Threat Landscape of Post-Quantum Cryptographic Exploits," puts the company in a short list of post-quantum security players chosen to brief the global hacker community—an endorsement that underscores the market's growing focus on quantum-ready defenses. Scope Technologies' upcoming QSE mobile app will carry the platform's encryption and secure messaging to iOS and Android, with features tuned for healthcare, legal, and financial users. The company is also widening its global footprint. It has teamed up with nonprofit World Cyber Health, the group behind Malware Village, to share QSE expertise with public and private security teams. New reseller deals with Asia-Pacific distributor COGITO and Swedish Microsoft partner Coegi Cloud AB open access to more than 40 000 institutional users. On the financing front, Scope Technologies secured a $2.8 million raise earlier this year, supported in part by First Majestic Silver Corp., a former pilot customer that is now a strategic investor. The second tranche, closed in April, will fund client onboarding, mobile rollouts, and further scaling of infrastructure and partner channels. By pairing fresh executive talent with a live, quantum-ready product, Scope is positioning itself as a go-to provider for businesses that need to secure data long after today's encryption standards expire. Allot Ltd. (NASDAQ: ALLT) has landed its biggest customer in five years, signing a multi-year deal worth "tens of millions" with a Tier-1 telecom operator in EMEA. The agreement bundles network intelligence, traffic control, and cybersecurity tools to protect both mobile and fixed lines. "This is a major customer win for Allot, the largest in five years, and is pivotal in our journey as we continue to expand our security and network intelligence presence across EMEA" said Eyal Harari, CEO of Allot. "We are excited with this new partnership as we leverage our unique technological advantages and core expertise to support all customer requirements as we progress with our 'security-first' strategy." The win widens Allot's regional reach and underlines growing demand for its security-first approach. Advanced Micro Devices, Inc. (NASDAQ: AMD) has teamed up with HCLTech to build " future-ready" AI, cloud, and digital solutions that help enterprises stay secure as technology shifts. "Through this expanded collaboration, AMD and HCLTech can provide businesses across multiple industries with the leading-edge technology solutions they need to accelerate innovation and drive long-term growth," said Dr. Lisa Su, Chair and CEO, AMD. "Combining HCLTech's expertise in digital transformation with our industry-leading EPYC, Instinct and Ryzen PRO processors will enable us to provide enterprises with customized, future-ready solutions that maximize the potential of AI, cloud computing and advanced analytics." The partners will co-invest in innovation labs and training programs that turn AMD EPYC and Instinct chips into tools for faster, safer data processing. The deal gives companies a tested path to modernize with long-term compatibility and reduced cyber-risk. Datadog, Inc. (NASDAQ: DDOG) has rolled out new AI-first security tools that watch every layer of the tech stack—from source code and data to live applications. The release bundles Code Security, LLM Observability, and an AI agent in Cloud SIEM that spots and fixes risks in real time. "AI has exponentially increased the ever-expanding backlog of security risks and vulnerabilities organizations deal with," said Prashant Prahlad, VP of Products, Security at Datadog. "This is because AI-native apps are not deterministic; they're more of a black box and have an increased surface area that leaves them open to vulnerabilities like prompt or code injection. The latest additions to Datadog's Security Platform provide preventative and responsive measures-powered by continuous runtime visibility-to strengthen the security posture of AI workloads, from development to production." These additions let customers secure fast-moving AI workloads before attackers can exploit fresh gaps. STMicroelectronics N.V. (NYSE: STM) has unveiled a human-presence-detection solution for laptops and PCs that pairs its FlightSense Time-of-Flight sensors with AI algorithms to cut power use by more than 20 percent per day while boosting privacy and security. "Building on the integration of ST FlightSense technology in more than 260 laptops and PC models launched in recent years, we are looking forward to see our new HPD solution contributing to make devices more energy-efficient, secure, and user-friendly," said Alexandre Balmefrezol, Executive Vice President and General Manager of the Imaging Sub-Group at STMicroelectronics. "As AI and sensor technology continue to advance, with greater integration of both hardware and software, we can expect to see even more sophisticated and intuitive ways of interacting with our devices, and ST is best positioned to continue to lead this market trend." The system enables hands-free Windows Hello log-ins, walk-away locking, and alerts if someone peers over the user's shoulder. By embedding these safeguards at the hardware level, ST is helping device makers future-proof user data against emerging threats. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Scope Technologies Corp. advertising and digital media from the company directly, and expects to paid a fee from Maynard Communication Ltd. for writing and content distribution. There may be 3rd parties who may have shares Scope Technologies Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Scope Technologies Corp. which were purchased as a part of a private placement and have also purchased shares in the open market. MIQ reserves the right to buy and sell, and will/has bought and sold shares of Scope Technologies Corp. and will continue to do so on an ongoing basis without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Malaysian Reserve
24-06-2025
- Business
- Malaysian Reserve
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ — Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Indaptus Therapeutics, Inc. (NASDAQ: INDP), Perspective Therapeutics, Inc. (NYSE-American: CATX), SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), and Autolus Therapeutics plc (NASDAQ: AUTL). Analysts at Nova One Advisor are currently projecting the global oncology drug market to hit US$366.24 billion by 2034, expanding at a 7.4% CAGR. Others are even more optimistic, with ResearchAndMarkets estimating the sector will reach US$866.1 billion by 2034, growing at a 10.8% CAGR, and Vision Research Reports anticipating the market will top US$903.81 billion by the same year, driven by accelerating demand for advanced diagnostics and treatments. All this points to an optimal timing period for breakout cancer stocks. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new chapter with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. With a background in high-value biotech transactions and late-stage development strategy, Kelly brings experience that may help position the company for its next phase of clinical and corporate progress. Prior to joining Oncolytics, Kelly was General Counsel at Ambrx Biopharma, where he played a key role in the company's $2 billion acquisition by Johnson & Johnson. He also advised a range of life sciences firms on partnerships, licensing, and M&A during his tenure at Kirkland & Ellis LLP and Lowenstein Sandler LLP. His arrival comes as Oncolytics continues advancing pelareorep, a viral-based immunotherapy being evaluated in combination with checkpoint inhibitors and other agents across multiple cancer indications. 'Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients,' said Jared Kelly, CEO of Oncolytics Biotech. 'With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders.' Kelly's appointment appears aligned with a focused strategy: advancing pelareorep through late-stage development while maintaining capital efficiency and openness to potential partnerships. The company's lead program continues to generate data that support further investigation across several difficult-to-treat cancers. Pelareorep already holds FDA Fast Track designation in two separate indications — metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) — a distinction that highlights regulatory interest in its potential. Across clinical studies, the viral-based immunotherapy has consistently shown signs of immune activation, combinability with checkpoint inhibitors and chemotherapy, and efficacy in heavily pretreated populations. In mPDAC, a Phase 2 cohort from the trial has reported objective response rates (ORR) above 60% in tumor-evaluable patients, exceeding historical benchmarks for this indication. Additional analyses have noted extended two-year survival rates compared to previous benchmarks. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) observed overall survival trends that support continued clinical evaluation. Elsewhere, a Phase 2 anal cancer cohort combining pelareorep with a checkpoint inhibitor demonstrated partial or complete response rates that exceeded historical control trials for checkpoint inhibitor monotherapy, suggesting potential utility beyond the company's lead programs. 'Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date,' said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. 'We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors.' Kelly's compensation framework includes equity-based awards and performance-linked incentives tied to future financings and strategic outcomes. The structure is designed to align leadership priorities with long-term shareholder value while reinforcing a disciplined approach to capital and partnership development. As multiple cohorts advance within the GOBLET study — including those in pancreatic and anal cancers backed by external funding and regulatory support — Oncolytics appears positioned to continue its progress with a blend of clinical momentum, financial flexibility, and sharpened strategic direction. Prior to Kelly's appointment, Oncolytics presented new data from its GOBLET trial at the 2025 ASCO Annual Meeting, highlighting pelareorep's ability to stimulate both innate and adaptive immune responses in metastatic pancreatic cancer. With fresh clinical insights and new leadership in place, the company appears positioned to advance both its scientific and strategic priorities in tandem. CONTINUED… Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the market include: Indaptus Therapeutics, Inc. (NASDAQ: INDP) recently initiated dosing in a Phase 1b/2 study arm testing its lead candidate Decoy20 with PD-1 inhibitor tislelizumab in advanced solid tumors. 'This is an important milestone in our clinical development,' said Jeffrey Meckler, CEO of Indaptus. 'We have long believed the Decoy platform has the potential to be a game-changing approach to treating solid tumors.' The combination is being evaluated in patients previously treated with checkpoint inhibitors or with tumor types typically unresponsive to immunotherapy. Early preclinical findings showed Decoy20 could synergize with PD-1 blockade to activate stronger anti-tumor immunity. The trial will monitor safety and preliminary signals of efficacy before broader enrollment. Perspective Therapeutics, Inc. (NYSE-American: CATX) has recently opened enrollment for Cohort 3 of its Phase 1/2a trial testing [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors. 'We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial,' commented Markus Puhlmann, Chief Medical Officer of Perspective. 'We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs.' The newly approved dose level represents a 20% increase over the previous cohort and will be evaluated for safety and early signals of efficacy. Interim results presented at American Society of Clinical Oncology (ASCO) Annual Meeting and Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting showed evidence of anti-tumor activity and favorable tolerability at lower doses. The company expects to submit additional clinical updates in the second half of 2025 following extended patient follow-up. SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) recently presented new preclinical data at the 2025 ASCO Annual Meeting showing that its CDK9 inhibitor SLS009 demonstrated potent activity in ASXL1-mutated colorectal cancer cell lines. 'These results provide strong rationale for continued advancement of SLS009 as a potential treatment for ASXL1-mutated cancers,' said Dr. Dragan Cicic, Senior Vice President, Chief Development Officer at SELLAS. 'The ability to selectively target ASXL1-driven tumors at concentrations well below the known safety threshold opens the door for tolerable and effective therapy. Based on the findings, we believe that ASXL1 mutation status could serve as a potential biomarker for response to SLS009 inhibition, which may allow us to further refine patient selection and improve outcomes. We look forward to presenting these results at ASCO.' In the study, 75% of lines with ASXL1 frameshift mutations responded at low nanomolar concentrations, while no response was observed in wild-type lines. These findings suggest that ASXL1 mutation status may serve as a potential biomarker for patient selection. Autolus Therapeutics plc (NASDAQ: AUTL) has released updated results from its FELIX study, showing that obe-cel, a next-generation CAR T cell therapy, may provide long-term remission for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). With a median follow-up of nearly 33 months, more than 50% of patients were still in remission at 24 months, and 38% had not needed any additional therapy. 'Obe-cel's durability of response without any subsequent therapy in two out of every five responders is a key factor leading the transformation of therapy for adult r/r B-ALL patients. At a median follow up of 33 months, we are encouraged to see a continuation of the long-term plateau we observed at the last data cut,' said Dr. Christian Itin, CEO of Autolus. 'A well-tolerated, effective, durable treatment option for ALL patients who often have a poor prognosis and have had multiple prior treatments is of significant clinical benefit.' The data suggested obe-cel could serve as a standalone option for some patients, reducing the need for transplants or further treatment. The company also reported a strong safety profile and plans to continue advancing obe-cel as a potential cornerstone in adult B-ALL care. Source: CONTACT: Equity Insider info@ 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Video – – – View original content:
Cision Canada
12-06-2025
- Business
- Cision Canada
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /CNW/ -- Equity Insider News Commentary – The 2025 ASCO Annual Meeting has wrapped, leaving behind a wave of cautious optimism across the oncology landscape. From advances in immunotherapy and CAR T-cell strategies to new applications in AI, diagnostics, and even exercise-based interventions, this year's gathering spotlighted a broad array of promising approaches. However, looming over the scientific excitement are concerns about proposed U.S. budget cuts, including a potential 40% reduction in funding for the National Cancer Institute (NCI). As public investment comes under pressure, many are turning to the private sector to carry the load — with recent moves by companies like Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Anixa Biosciences, Inc. (NASDAQ: ANIX), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), and ImmunityBio, Inc. (NASDAQ: IBRX). The rising global burden of cancer is driving urgent demand for next-generation therapies. By 2030, annual case counts are expected to climb 20%, with projections pointing to a 75% surge by 2050, according to Statista. Market researchers anticipate oncology spending will scale to match: ResearchAndMarkets forecasts the sector hitting US$866.1 billion by 2034, growing at a 10.8% CAGR, while Vision Research Reports places the market for cancer treatments even higher — surpassing US$903.81 billion at a 10.9% CAGR. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), just announced a major leadership transition that could mark a pivotal chapter in its clinical and corporate trajectory. The company has appointed Jared Kelly as Chief Executive Officer and member of the Board, a move that brings in a seasoned biotech dealmaker known for high-value M&A and immuno-oncology strategy. Kelly most recently played a central role (as General Counsel) in the $2 billion sale of Ambrx Biopharma to Johnson & Johnson. Prior to that, he advised numerous biotech firms on licensing and acquisitions during his tenure at leading law firms Kirkland & Ellis LLP and Lowenstein Sandler LLP. In joining Oncolytics, he inherits one of the most intriguing immunotherapy agents and pipelines in clinical oncology: pelareorep, a virus-based agent with broad synergy potential in solid and hematologic tumors. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly, CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders." Kelly's appointment signals a clear priority: advancing pelareorep toward late-stage inflection points with a capital-efficient and partnership-aware strategy. The asset currently holds FDA Fast Track designation in both metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) —a rare distinction that reinforces its regulatory momentum. In trials to date, pelareorep has consistently demonstrated immune activation, synergy with chemotherapies and checkpoint inhibitors, and unusually strong response rates across difficult-to-treat cancers. In metastatic pancreatic cancer (mPDAC), pelareorep has delivered over 60% objective response rates in tumor evaluable patients across Phase 1 and 2 studies—more than double those observed in historical controls — and, separately, two-year survival rates 4-6 times those observed in control patients or in prior studies. In HR+/HER2- metastatic breast cancer, two randomized Phase 2 trials (IND-213 and BRACELET-1) showed meaningful survival benefit. And in anal cancer, early data from a phase 2 cohort combining pelareorep with a checkpoint inhibitor showed partial or complete responses in nearly half of evaluable patients—far exceeding historical norms for monotherapy. "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." To align incentives with long-term shareholder value, Kelly's compensation package includes equity and milestone-based awards tied to future strategic transactions and financings. The structure reflects Oncolytics' intention to drive both clinical and corporate progress without overextending its cap table—while remaining attractive to potential collaborators. As multiple programs advance within the GOBLET study—including pancreatic and anal cancer cohorts backed by regulatory support and third-party funding— Oncolytics appears poised to benefit from a combination of scientific traction, capital flexibility, and strategic leadership. In other recent industry developments and happenings in the market include: Anixa Biosciences, Inc. (NASDAQ: ANIX) is advancing two novel programs at the frontlines of cancer immunotherapy. The company will present new data from its first-in-human ovarian cancer CAR-T clinical trial later this month at the ESMO Gynaecological Cancers Congress, showcasing a unique chimeric endocrine receptor T-cell (CER-T) platform targeting the follicle stimulating hormone receptor (FSHR). Separately, Anixa is also working with Cleveland Clinic to develop a preventative breast cancer vaccine designed to train the immune system to recognize "retired" proteins reactivated in early malignancies. "While cancer vaccines have traditionally faced significant hurdles, our approach is aimed at a novel target that has not been previously explored in this context," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "We believe this could represent a new paradigm in immuno-oncology. The breast cancer market, particularly for triple-negative breast cancer and genetically high-risk populations, continues to face a major unmet need. Our vaccine may offer a unique, immunologic pathway for both prevention and treatment." Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has published the final five-year analysis from its Phase 2 C-144-01 trial evaluating Amtagvi® (lifileucel), the first FDA -approved T cell therapy for solid tumors in patients with advanced melanoma. "Amtagvi has demonstrated long-term benefit and meaningful overall survival in a difficult-to-treat melanoma patient population resistant to immune checkpoint inhibitor therapy," said Theresa Medina, M.D., medical oncologist at the University of Colorado Cancer Center on the Anschutz Medical Campus. "Five years following one-time Amtagvi treatment, responses persisted or deepened during an extended treatment-free interval for some patients. Amtagvi offers a new standard of care for the advanced melanoma community and sets a new bar for one-time cell therapies with curative intent in solid tumors." The results, featured in the Journal of Clinical Oncology and presented at ASCO 2025, highlight durable responses in heavily pretreated patients—with nearly one-third of responders maintaining benefit five years after a single treatment. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) recently reported compelling Phase 3 results for Libtayo® (cemiplimab) as an adjuvant therapy in patients with high-risk cutaneous squamous cell carcinoma (CSCC) following surgery. The trial showed a 68% reduction in disease recurrence or death and strong secondary endpoint performance, including 80% and 65% reductions in locoregional and distant recurrence, respectively. "The Phase 3 C-POST trial demonstrates that cemiplimab is a highly active therapy in high-risk CSCC, with clinically meaningful outcomes across primary and secondary endpoints and exceptionally low rates of locoregional and distant recurrence," said Danny Rischin, M.D., Head of Head and Neck Cancer and Cutaneous SCC at Peter MacCallum Cancer Centre. "While surgery and radiotherapy remain the cornerstones of treatment, there is a critical unmet need for systemic therapies to help prevent relapse and metastasis." Regulatory filings have already been submitted in the U.S. and EU, and experts say these findings could reshape treatment standards. ImmunityBio, Inc. (NASDAQ: IBRX) is advancing what may be the first true therapy for lymphopenia—a condition long associated with poor outcomes in cancer but never directly treated until now. "Lymphopenia has long been recognized as a major driver and predictor of early mortality in cancer—yet until now, it has remained unaddressed," said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. " Backed by FDA Expanded Access authorization, the company's Cancer BioShield™ platform centers on ANKTIVA®, an IL-15 superagonist approved in bladder cancer and now being deployed to help restore immune function in patients with solid tumors who've exhausted first-line therapies. "This FDA authorization allows all patients with solid tumors suffering from immune collapse following first-line therapy of chemo, radiation, or immunotherapy to access ANKTIVA," said Soon-Shiong. "The survival benefit we observed at ASCO 2025 in 3 rd to 6 th line advanced metastatic pancreatic cancer confirms that restoring lymphocyte levels—rather than depleting them—can change the course of disease." At ASCO 2025, ImmunityBio presented landmark data showing that reversing lymphopenia with ANKTIVA and CAR-NK cells significantly extended survival in late-stage pancreatic cancer patients, especially when intervention occurred at a lower tumor burden. The results represent a potential paradigm shift: treating immune collapse itself—not just the tumor—may drive better long-term outcomes. Based on this mechanism, the platform could open doors to broader applications in oncology, infectious disease, and immune senescence. CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Associated Press
23-05-2025
- Business
- Associated Press
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 23, 2025 /PRNewswire/ -- Equity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is increasingly being shaped not by public institutions, but by the breakthroughs emerging from the private sector. For investors watching the next wave of oncology breakthroughs, companies like Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Akoya Biosciences, Inc. (NASDAQ: AKYA), Quanterix Corporation (NASDAQ: QTRX), TScan Therapeutics, Inc. (NASDAQ: TCRX), and Arcellx, Inc. (NASDAQ: ACLX) are increasingly standing out. Cancer treatment markets are on track for massive expansion over the next decade. Immunotherapy, in particular, is expected to reach an annual market size of US$1.2 trillion by 2033, driven by a compound annual growth rate of 18%, according to analysts at Precedence Research. Meanwhile, global oncology spending overall is projected by Vision Research Reports to surpass US$900 billion, climbing at an estimated 11% per year. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) is gaining new visibility ahead of its upcoming presentation at the 2025 ASCO Annual Meeting, where the company will unveil new clinical trial data on pelareorep's immunological activity in pancreatic cancer. The data, drawn from the GOBLET study, highlights how pelareorep appears to convert immunologically 'cold' tumors into 'hot,' inflamed environments—potentially making them more vulnerable to immune attack. Specifically, new analyses show pelareorep induces a pro-inflammatory tumor microenvironment (TME) and activates both innate and adaptive immunity. This is a rare achievement in pancreatic ductal adenocarcinoma (PDAC), a cancer type widely considered resistant to immune-based therapies. 'For the first time, we're able to map the cascade of immune responses stimulated by pelareorep,' said Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics. 'It starts with the expansion of anti-reovirus T cells, followed by the upregulation of chemokines that mediate the expansion of pre-existing TIL (tumor-infiltrating lymphocyte) clones in the blood.' According to Heineman, these immune cells don't just expand in the bloodstream—they're believed to return to the tumor itself and help shrink it. 'These T cells can now return to the tumor and attack it, resulting in a reduction in tumor size,' Heineman added. 'Pelareorep-mediated upregulation of chemokines also makes the tumor microenvironment immunologically active and able to actively recruit cancer-specific T cells to the tumor. These findings deepen our understanding of pelareorep's ability to convert immunologically cold tumors into immunologically active ones that may benefit from pelareorep-based combination therapy.' The abstract, titled 'Role of pelareorep in activating anti-tumor immunity in PDAC,' (Abstract #2562) will be presented as a poster during the Developmental Therapeutics – Immunotherapy session on June 2, 2025. A copy will be made available on the Media page of Oncolytics' website following the session. This new mechanistic insight builds on prior efficacy data from GOBLET Cohort 1, where pelareorep—combined with nab-paclitaxel, gemcitabine, and the checkpoint inhibitor atezolizumab—produced a 62% overall response rate, 85% disease control rate, and 45% 12-month survival rate in first-line metastatic PDAC patients. For context, GOBLET is a multi-cohort, phase 1/2 study evaluating pelareorep in combination with various immunotherapy and chemotherapy regimens across gastrointestinal cancers. Conducted in partnership with AIO-Studien-gGmbH in Germany, the trial uses an adaptive design: cohorts meeting efficacy thresholds may expand enrollment. In pancreatic cancer, this trial is a proving ground for pelareorep's use in first-line and newly diagnosed settings—potentially setting up future pivotal decisions. Progress continues elsewhere in the GOBLET study as well. In Cohort 5, newly diagnosed metastatic PDAC patients received pelareorep with modified FOLFIRINOX, with or without atezolizumab. After completing the safety run-in in six evaluable patients, the study has been cleared to proceed by both Germany's Paul-Ehrlich-Institut and an independent data safety monitoring board. This arm is backed by a US$5 million PanCAN grant, with further data expected in 2026. Favorable data from this cohort could expand pelareorep's potential addressable market in this indication. Meanwhile, in anal cancer, Cohort 4 has already reported signs of durable response. Of 12 evaluable patients treated with pelareorep and atezolizumab, four achieved partial responses, and one reached a complete response lasting more than 15 months—results that surpass historical benchmarks for checkpoint inhibitors alone. The cohort is now being expanded to validate these findings and assess registrational potential. In breast cancer, the recently completed randomized phase 2 BRACELET-1 trial in HR+/HER2- metastatic disease showed patients receiving pelareorep plus paclitaxel nearly doubled their progression-free survival compared to paclitaxel alone. These outcomes are supportive of those seen in a prior randomized phase 2 study and strengthen the case for a pivotal trial. Key opinion leaders continue backing pelareorep's approach. In a recent panel hosted by H.C. Wainwright, Profs. Martine Piccart and Alexander Eggermont emphasized how pelareorep may help 'turn cold tumors hot"—a key requirement for making immunotherapies effective in traditionally resistant cancers. While still in the clinical development stage, pelareorep has demonstrated compatibility with multiple chemotherapies and checkpoint inhibitors, suggesting it could function as a plug-in immune booster across diverse treatment regimens. Its intravenous delivery, systemic impact, and favorable safety profile further support its adaptability in combination trials. 'Pelareorep continues to build clinical momentum, delivering encouraging results in challenging cancer types and has the potential to extend and improve the lives of patients,' said Wayne Pisano, Chair of Oncolytics' Board of Directors and Interim CEO. 'This versatility and broad potential applicability are achieved via intravenous administration and the ability to combine with chemotherapies and checkpoint inhibitors while maintaining a favorable safety profile.' As it stands, Oncolytics may be entering a stretch where scientific validation, clinical optionality, and capital flexibility are all converging. The company ended Q1 2025 with $15.3 million in cash and a US$20 million equity facility from Alumni Capital, giving it financing control without restrictive terms or dilutive warrants. With fresh data coming out of ASCO and multiple arms of GOBLET advancing, pelareorep's immune-activating potential appears to be gaining traction across an expanding range of solid tumor indications. Infographic - CONTINUED… Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the market include: Akoya Biosciences, Inc. (NASDAQ: AKYA) recently reported Q1 2025 revenue of $16.6 million, with a 12% year-over-year increase in installed instruments and a 44.7% rise in total publications. Gross margin improved to 59.3%, and operating losses narrowed 38% compared to the same quarter last year. The company highlighted major cancer collaborations in the U.S. and Singapore, along with a new ADC breast cancer assay unveiled at AACR. This comes just two weeks after Akoya and Quanterix Corporation (NASDAQ: QTRX) announced amended terms to their merger agreement, reducing share issuance by over 9 million while preserving a $20 million cash component. The merger brings together two complementary platforms—spatial phenotyping and ultra-sensitive biomarker detection—aimed at accelerating next-generation precision diagnostics across oncology and immunology. 'We remain excited to combine with Quanterix and believe this partnership offers compelling value for Akoya shareholders,' said Brian McKelligon, CEO of Akoya Biosciences. 'We look forward to closing the transaction and leveraging our collective scale to drive synergies across our organizations and customers, expediting our path to profitability.' Akoya shareholders are now set to receive $0.38 per share in cash and 0.1461 shares of Quanterix common stock. 'The strategic merits of the transaction remain strong even as the market has been focused on academic funding and tariff concerns,' said Masoud Toloue, PhD, CEO of Quanterix. 'The combined company will provide a significant value creation opportunity for shareholders.' The transaction is expected to close in Q2 2025, positioning the combined company as a scaled leader in spatial biology and ultra-sensitive biomarker detection. TScan Therapeutics, Inc. (NASDAQ: TCRX) posted Q1 2025 revenue of $2.2 million, driven by collaboration activity with Amgen, and ended the quarter with $251.7 million in cash and marketable securities. 'This is an exciting year for TScan as we advance our mission of bringing life-changing T-cell therapies to patients with both heme and solid tumor malignancies,' said Gavin MacBeath, Ph.D., CEO of TScan Therapeutics. 'We look forward to dosing our first patient with multiplex therapy soon, and to sharing safety and efficacy data later this year.' Net loss for the quarter was $34.1 million, with R&D spending up due to manufacturing scale-up and preclinical work. The company is actively enrolling patients in two ongoing Phase 1 studies: ALLOHA in heme malignancies and PLEXI-T in solid tumors. Key milestones this year include a planned IND submission, a registrational trial initiation, and clinical data readouts from both trials. Arcellx, Inc. (NASDAQ: ACLX) recently reported new data from its Phase 2 iMMagine-1 study showing a 97% overall response rate and 68% complete/stringent complete response rate in heavily pretreated multiple myeloma patients. No delayed neurotoxicities or immune-mediated enterocolitis have been observed to date, with safety and durability metrics continuing to impress at 12.6 months median follow-up. 'These clinical data from our registrational study continue to support our belief that anito-cel has the potential to address the needs of myeloma patients and the physicians who serve them,' said Rami Elghandour, CEO of Arcellx. 'There is no cure for multiple myeloma. We believe there remains an unmet medical need for CAR-T therapies that are efficacious, safe, and accessible.' The data will be presented in an oral session at EHA2025, ahead of a planned commercial launch in 2026 with partner Kite, a Gilead company. Source: CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Video - Logo - View original content to download multimedia: SOURCE Equity Insider
Associated Press
23-05-2025
- Business
- Associated Press
AI Could Add $461 Billion to Global Healthcare--And These New Platforms Are Leading the Charge
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 23, 2025 /PRNewswire/ -- Equity Insider News Commentary – A new report from Philips reveals a growing divide between doctors and patients when it comes to AI in healthcare. While 63% of surveyed healthcare professionals believe AI can help improve outcomes, only 48% of patients share that optimism. As researchers explore what's needed for successful AI adoption in healthcare, major players in tech and biotech are already moving ahead—recent updates have come from Avant Technologies, Inc. (OTCQB: AVAI), Renovaro Inc. (NASDAQ: RENB), Certara, Inc. (NASDAQ: CERT), CareCloud, Inc. (NASDAQ: CCLD), and Microsoft Corporation (NASDAQ: MSFT). Analysts at MarketsandMarkets expect the AI healthcare sector to grow at a 38.6% CAGR, topping $110 billion by 2030. Accenture goes even further, estimating AI could inject another $461 billion in added value by 2035—amplifying impact across a global healthcare system already on track to surpass $2.26 trillion. Avant Technologies, Inc. (OTCQB: AVAI), in partnership with Ainnova Tech, is positioning its Vision AI platform at the forefront of predictive healthcare. The company is in advanced discussions to acquire or exclusively license a patented early disease detection technology that could significantly enhance its diagnostic capabilities. If finalized, the deal would allow Vision AI to generate clinical insights even in the absence of a complete patient dataset—unlocking earlier intervention opportunities and supporting a more proactive model of care. 'Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily,' said Vinicio Vargas, CEO at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp. (AAC), said of AAC's aim to continue to add to its portfolio. 'We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions.' The potential acquisition aligns with Avant and Ainnova's shared mission to deliver scalable, preventive health tools that merge retinal imaging, vital sign monitoring, and machine learning into one streamlined platform. Vision AI is already positioned as a next-generation diagnostic engine for chronic conditions like diabetes, cardiovascular disease, and kidney dysfunction. Now, the joint venture is pushing further—evaluating breakthrough technologies that could detect emerging health issues at a pre-symptomatic stage. Recent platform updates saw four proprietary algorithms—trained on over 2.3 million real-world clinical cases—fully integrated into Vision AI. The addition of new IP from this proposed deal would mark a significant leap forward, enabling predictive models to extract meaningful signals from even limited patient data. Avant and Ainnova view this initiative as part of a broader strategy to consolidate breakthrough tools that make early disease detection more scalable, mobile, and applicable across diverse healthcare settings. While a final agreement has yet to be announced, the companies have stated they will keep shareholders informed as developments progress. In parallel, Avant has entered formal discussions to acquire Ainnova outright—building on their existing alignment under the Ai-nova Acquisition Corp. (AAC) structure. The timing is deliberate, coming just ahead of a planned FDA pre-submission meeting this July. A completed merger would unify operations, reduce internal complexity, and bolster the joint venture's regulatory readiness as it prepares for potential U.S. market entry. 'We believe bringing the two companies together will offer tremendous value for shareholders,' said Vargas. 'It will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally.' At the center of this initiative is Vision AI—a non-invasive screening platform that integrates retinal imaging, vital sign monitoring, and machine-learning models to flag early indicators of chronic disease. The system targets conditions such as diabetic retinopathy, cardiovascular issues, kidney and liver disorders, and type 2 diabetes. Operated under the AAC structure, the joint venture holds global rights to Vision AI, which has demonstrated over 90% sensitivity in early detection based on research cited by the NIH. 'This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where Vision AI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market,' said Vargas. 'Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product.' While many AI healthcare platforms remain stuck in pilot stages, Avant's Vision AI is already live across multiple Latin American markets —including Chile, Mexico, and Brazil —where it's actively being used in clinical settings. These real-world deployments are generating essential data on safety and efficacy, while also providing user feedback that guides ongoing system improvements. To broaden its diagnostic reach, the Ai-nova joint venture recently integrated four additional algorithms into the platform. Each was trained on a dataset of more than 2.3 million clinical records, enhancing Vision AI's precision across a wider spectrum of chronic diseases. With active momentum abroad and U.S. regulatory discussions now underway, Avant's trajectory appears to be moving from early validation toward broader market penetration. CONTINUED... Read this and more news for Avant Technologies at: Renovaro Inc. (NASDAQ: RENB) has officially launched Augusta, a next-generation AI-powered platform targeting precision neurology. Designed for patient stratification, biomarker discovery, and accelerated drug development, Augusta integrates multiomics, contingent AI, phenoclustering, and in silico screening into one modular system. 'The Augusta platform is about validation,' said David Weinstein, CEO of Renovaro Inc. 'We're setting a new bar for how AI can be responsibly and effectively deployed in clinical and experimental settings.' The platform has already demonstrated early success in Parkinson's disease and epilepsy, with expansion plans underway for additional neurological conditions. Certara, Inc. (NASDAQ: CERT) has launched its Non-Animal Navigator™ solution to help drug developers reduce reliance on animal testing, aligning with the FDA's Roadmap to Reducing Animal Testing in Preclinical Safety Studies. 'The FDA announcement and roadmap pave the way for more model-informed drug development approaches that are predictive, efficient, and ethical,' said William F. Feehery, CEO of Certara Inc. 'It is part of a growing industry adoption trend to use scientifically robust new approach methodologies (NAMs) like AI-enabled biosimulation to improve strategic decision-making and success rates at every phase of drug development.' The new offering combines strategic regulatory guidance with AI-enabled biosimulation, providing an ethical and efficient pathway through early-stage drug development. With adoption already underway, Certara's platform offers a future-ready model for companies advancing biologics, including monoclonal antibodies and ADCs. CareCloud, Inc. (NASDAQ: CCLD) has been named Maxim Group's " Top Healthcare IT Pick for 2025,' with analysts citing the company's AI-first strategy, strong financial performance, and discounted valuation as key drivers. 'AI is now deeply integrated into our operations—from documentation and revenue cycle management to patient engagement and analytics,' said Hadi Chaudhry, Co-CEO of CareCloud Inc. 'This is not an add-on, it is a foundational capability that is changing how healthcare is delivered and experienced.' The firm recently launched its AI Center of Excellence and introduced purpose-built tools like cirrusAI Notes and cirrusAI Voice to streamline clinical workflows and improve patient engagement. CareCloud plans to scale its AI team from 50 to 500 by year-end, deepening its role as a leader in applied healthcare AI. Microsoft Corporation (NASDAQ: MSFT) has introduced its healthcare agent orchestrator —a multi-agent AI framework designed to support complex clinical workflows, such as tumor boards, by analyzing multimodal data across imaging, genomics, and electronic health records. 'The vision of the healthcare agent orchestrator is to rapidly surface, summarize, and take action on relevant multimodal medical information for each complex cancer case, so hours of review can become minutes,' said Dr. Joshua Warner, Radiologist at UW Health and Assistant Professor of Radiology, UW School of Medicine and Public Health. 'Collaborating with Microsoft allows us to explore the value of these models for tumor boards and beyond.' Now available through Azure AI Foundry, the system enables clinicians and developers to coordinate specialized AI agents directly within Microsoft Teams and Office tools, streamlining hours of expert analysis into minutes. Leading institutions like Stanford, Johns Hopkins, and Providence are already piloting the technology to accelerate cancer diagnosis, clinical trial matching, and treatment planning. Source: CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Video - Logo - View original content to download multimedia: SOURCE Equity Insider
